Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Design Therapeutics (NASDAQ:DSGN) announced its quarterly earnings results on Monday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02, Yahoo Finance reports.

Design Therapeutics Stock Performance

NASDAQ DSGN opened at $4.21 on Wednesday. The firm’s fifty day moving average is $3.99 and its two-hundred day moving average is $3.55. Design Therapeutics has a one year low of $1.94 and a one year high of $7.83. The firm has a market cap of $237.84 million, a PE ratio of -4.01 and a beta of 1.83.

Analyst Ratings Changes

A number of research firms recently commented on DSGN. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.60.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.